CCRC (CLINICAL RESEARCH COORDINATOR) – PRACTICE QUESTIONS AND CORRECT ANSWERS
(VERIFIED ANSWERS) PLUS RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF.
Core Domains
- Recruitment and Retention of Study Participants- Protocol Management and Compliance- Safety Monitoring
and Adverse Event Reporting- Investigational Product Management- Regulatory Requirements and
Documentation- Ethical Principles and Human Subject Protection- Data Management and Source
Documentation- Clinical Trial Budgeting and Operations
Introduction
This comprehensive assessment is designed to evaluate the core competencies required of a Clinical Research
Coordinator (CCRC). The purpose of this exam is to ensure proficiency in the regulatory, ethical, and
operational aspects of clinical trials. Candidates are assessed on their ability to manage study protocols, protect
human subjects, and maintain data integrity according to Good Clinical Practice (GCP) and FDA guidelines.
The exam utilizes a mix of multiple-choice and complex scenario-based questions to mirror real-world
application. Emphasis is placed on critical decision-making, professional ethics, and the practical execution of
clinical research tasks in a high-stakes environment.
Section One: Questions 1–100
1. Which document serves as the primary guideline for the ethical conduct of clinical research involving
human subjects globally?
A. The Nuremberg Code
B. The Declaration of Helsinki
C. The Belmont Report
D. The Common Rule
🟢 Correct answer B.
🔴 RATIONALE: While all listed are ethical milestones, the Declaration of Helsinki is the primary international
ethical framework developed by the World Medical Association for medical research involving human subjects.
, 2. A Clinical Research Coordinator (CRC) notices that a laboratory refrigerator containing study samples is
at 10 degrees Celsius, while the protocol requires 2 to 8 degrees. What is the immediate first step?
A. Discard all samples immediately
B. Move the samples to a functioning refrigerator and document the deviation
C. Call the sponsor to ask for a waiver
D. Adjust the thermostat and wait two hours to recheck
🟢 Correct answer B.
🔴 RATIONALE: The immediate priority is to stabilize the samples to prevent further degradation, followed by
meticulous documentation of the temperature excursion and notification of the PI and Sponsor.
3. During an Informed Consent discussion, a potential participant asks if they can withdraw from the study if
they change their mind later. The CRC should respond that:
A. They can withdraw only after the first 30 days
B. They can withdraw at any time without penalty or loss of benefits
C. Withdrawal requires a written 14-day notice
D. They are legally bound to complete the study once the drug is administered
🟢 Correct answer B.
🔴 RATIONALE: Under GCP and federal regulations, participation must be voluntary, and subjects must be
informed they can withdraw at any time without consequence.
4. Which of the following is considered a "Serious Adverse Event" (SAE)?
A. A mild headache that resolved with aspirin
B. An unexpected visit to the primary care physician for a cold
C. Hospitalization for an elective procedure planned before study entry
D. A life-threatening complication during a study-related procedure
🟢 Correct answer D.
,🔴 RATIONALE: An SAE is defined by outcomes such as death, life-threatening instances, inpatient
hospitalization, or significant disability; life-threatening complications meet this threshold.
5. What is the primary purpose of a "Source Document" in a clinical trial?
A. To provide a summary for the FDA
B. To serve as the first place data is recorded and to verify the data on the CRF
C. To replace the electronic data capture system
D. To list the contact information of all study investigators
🟢 Correct answer B.
🔴 RATIONALE: Source documentation is the original record used to substantiate the existence of the
participant and the integrity of the data collected during the trial.
6. A protocol amendment is issued that changes the dosage of the investigational product. What must occur
before currently enrolled subjects can receive the new dose?
A. The PI must verbally approve the change
B. The IRB must approve the amendment and subjects must sign a revised consent form
C. The CRC simply updates the dosage on the next visit
D. No action is needed if the dose change is minor
🟢 Correct answer B.
🔴 RATIONALE: Any significant change to the protocol or risk-benefit ratio requires IRB approval and re-
consenting of active participants to ensure they are informed of the changes.
7. According to ICH GCP, who is ultimately responsible for the conduct of the study at the site?
A. The Clinical Research Coordinator
B. The Sponsor
C. The Principal Investigator
D. The Institutional Review Board
🟢 Correct answer C.
, 🔴 RATIONALE: While tasks can be delegated to the CRC, the Principal Investigator (PI) retains ultimate legal
and ethical responsibility for the conduct of the trial at the site.
8. A subject misses a study visit window due to a family emergency. How should the CRC handle this?
A. Backdate the visit to the day it should have occurred
B. Delete the visit from the schedule as if it never existed
C. Document the missed visit as a protocol deviation
D. Schedule two visits back-to-back to catch up on data
🟢 Correct answer C.
🔴 RATIONALE: Accuracy and transparency are vital; a missed window is a protocol deviation and must be
documented and reported per site and sponsor policy.
9. Which of the following best describes "blinding" in a clinical trial?
A. Keeping the study results secret from the general public
B. Ensuring the participant does not know which treatment they are receiving
C. Preventing the IRB from seeing the names of the participants
D. Hiding the identity of the sponsor from the investigators
🟢 Correct answer B.
🔴 RATIONALE: Blinding is a procedure to prevent bias by ensuring participants (single-blind) or both
participants and investigators (double-blind) do not know the treatment assignment.
10. When a CRC is performing "drug accountability," they are primarily checking for:
A. The chemical purity of the drug
B. The market price of the drug
C. The reconciliation of units received, dispensed, returned, and destroyed
D. The side effects reported by the patient
🟢 Correct answer C.
(VERIFIED ANSWERS) PLUS RATIONALES 2026 Q&A | INSTANT DOWNLOAD PDF.
Core Domains
- Recruitment and Retention of Study Participants- Protocol Management and Compliance- Safety Monitoring
and Adverse Event Reporting- Investigational Product Management- Regulatory Requirements and
Documentation- Ethical Principles and Human Subject Protection- Data Management and Source
Documentation- Clinical Trial Budgeting and Operations
Introduction
This comprehensive assessment is designed to evaluate the core competencies required of a Clinical Research
Coordinator (CCRC). The purpose of this exam is to ensure proficiency in the regulatory, ethical, and
operational aspects of clinical trials. Candidates are assessed on their ability to manage study protocols, protect
human subjects, and maintain data integrity according to Good Clinical Practice (GCP) and FDA guidelines.
The exam utilizes a mix of multiple-choice and complex scenario-based questions to mirror real-world
application. Emphasis is placed on critical decision-making, professional ethics, and the practical execution of
clinical research tasks in a high-stakes environment.
Section One: Questions 1–100
1. Which document serves as the primary guideline for the ethical conduct of clinical research involving
human subjects globally?
A. The Nuremberg Code
B. The Declaration of Helsinki
C. The Belmont Report
D. The Common Rule
🟢 Correct answer B.
🔴 RATIONALE: While all listed are ethical milestones, the Declaration of Helsinki is the primary international
ethical framework developed by the World Medical Association for medical research involving human subjects.
, 2. A Clinical Research Coordinator (CRC) notices that a laboratory refrigerator containing study samples is
at 10 degrees Celsius, while the protocol requires 2 to 8 degrees. What is the immediate first step?
A. Discard all samples immediately
B. Move the samples to a functioning refrigerator and document the deviation
C. Call the sponsor to ask for a waiver
D. Adjust the thermostat and wait two hours to recheck
🟢 Correct answer B.
🔴 RATIONALE: The immediate priority is to stabilize the samples to prevent further degradation, followed by
meticulous documentation of the temperature excursion and notification of the PI and Sponsor.
3. During an Informed Consent discussion, a potential participant asks if they can withdraw from the study if
they change their mind later. The CRC should respond that:
A. They can withdraw only after the first 30 days
B. They can withdraw at any time without penalty or loss of benefits
C. Withdrawal requires a written 14-day notice
D. They are legally bound to complete the study once the drug is administered
🟢 Correct answer B.
🔴 RATIONALE: Under GCP and federal regulations, participation must be voluntary, and subjects must be
informed they can withdraw at any time without consequence.
4. Which of the following is considered a "Serious Adverse Event" (SAE)?
A. A mild headache that resolved with aspirin
B. An unexpected visit to the primary care physician for a cold
C. Hospitalization for an elective procedure planned before study entry
D. A life-threatening complication during a study-related procedure
🟢 Correct answer D.
,🔴 RATIONALE: An SAE is defined by outcomes such as death, life-threatening instances, inpatient
hospitalization, or significant disability; life-threatening complications meet this threshold.
5. What is the primary purpose of a "Source Document" in a clinical trial?
A. To provide a summary for the FDA
B. To serve as the first place data is recorded and to verify the data on the CRF
C. To replace the electronic data capture system
D. To list the contact information of all study investigators
🟢 Correct answer B.
🔴 RATIONALE: Source documentation is the original record used to substantiate the existence of the
participant and the integrity of the data collected during the trial.
6. A protocol amendment is issued that changes the dosage of the investigational product. What must occur
before currently enrolled subjects can receive the new dose?
A. The PI must verbally approve the change
B. The IRB must approve the amendment and subjects must sign a revised consent form
C. The CRC simply updates the dosage on the next visit
D. No action is needed if the dose change is minor
🟢 Correct answer B.
🔴 RATIONALE: Any significant change to the protocol or risk-benefit ratio requires IRB approval and re-
consenting of active participants to ensure they are informed of the changes.
7. According to ICH GCP, who is ultimately responsible for the conduct of the study at the site?
A. The Clinical Research Coordinator
B. The Sponsor
C. The Principal Investigator
D. The Institutional Review Board
🟢 Correct answer C.
, 🔴 RATIONALE: While tasks can be delegated to the CRC, the Principal Investigator (PI) retains ultimate legal
and ethical responsibility for the conduct of the trial at the site.
8. A subject misses a study visit window due to a family emergency. How should the CRC handle this?
A. Backdate the visit to the day it should have occurred
B. Delete the visit from the schedule as if it never existed
C. Document the missed visit as a protocol deviation
D. Schedule two visits back-to-back to catch up on data
🟢 Correct answer C.
🔴 RATIONALE: Accuracy and transparency are vital; a missed window is a protocol deviation and must be
documented and reported per site and sponsor policy.
9. Which of the following best describes "blinding" in a clinical trial?
A. Keeping the study results secret from the general public
B. Ensuring the participant does not know which treatment they are receiving
C. Preventing the IRB from seeing the names of the participants
D. Hiding the identity of the sponsor from the investigators
🟢 Correct answer B.
🔴 RATIONALE: Blinding is a procedure to prevent bias by ensuring participants (single-blind) or both
participants and investigators (double-blind) do not know the treatment assignment.
10. When a CRC is performing "drug accountability," they are primarily checking for:
A. The chemical purity of the drug
B. The market price of the drug
C. The reconciliation of units received, dispensed, returned, and destroyed
D. The side effects reported by the patient
🟢 Correct answer C.
